4078-65-3

Usage

Uses

Used in Pharmaceutical Industry:
N-(3,4-Dimethoxyphenethyl)-2-(4-methoxyphenyl)acetamide is used as a key intermediate in the synthesis of (-)-Higenamine (H325800), a compound with potential therapeutic applications. Its role in the synthesis process is crucial for the production of the final pharmaceutical product, highlighting its importance in the development of new medications.

Upstream product

• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 4693-91-8 4-methoxyphenyl-acetic chloride 
• 4230-93-7 1,2-dimethoxy-4-(2-nitro-vinyl)-benzene 
• 1798-09-0 m-methoxyphenylacetic acid 
• 6834-42-0 3-methoxyphenylacetic acid chloride 
• 104-01-8 4-Methoxyphenylacetic acid 

Downstream Products

• 72527-29-8 6,7-dimethoxy-1-(4-methoxybenzyl)-3,4-dihydroisoquinoline 
• 77354-33-7 (+/-)-1-(4-methoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline hydrochoride 
• 64229-29-4 C₄₈H₆₂N₂O₁₀⁽²⁺⁾*2I^(1-) 
• 81165-37-9 3-[6,7-Dimethoxy-1-(4-methoxy-benzyl)-3,4-dihydro-1H-isoquinolin-2-yl]-propionic acid 2-{3-[6,7-dimethoxy-1-(4-methoxy-benzyl)-3,4-dihydro-1H-isoquinolin-2-yl]-propionyloxy}-ethyl ester; compound with oxalic acid 
• 3991-23-9 6,7-dimethoxy-1-(4-methoxy-benzyl)-2-methyl-3,4-dihydro-isoquinolinium; iodide 
• 41498-37-7 7,12-O,O'-dimethylcoclaurine 
• 13233-00-6 6,7-dimethoxy-1-(4-methoxybenzyl)-3,4-dihydroisoquinoline hydrochloride 
• 1443828-60-1 ((6,7-dimethoxy-1-(3-methoxybenzyl)-3,4-dihydroisoquinolin-2(1H)-yl)(phenyl)methanone) 
• 1443828-58-7 ((6,7-dimethoxy-1-(4-methoxybenzyl)-3,4-dihydroisoquinolin-2(1H)-yl)(phenyl)methanone) 
• 1443828-59-8 ((3-chlorophenyl)(6,7-dimethoxy-1-(4-methoxybenzyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone) 
• 17052-80-1 (6,7-dimethoxy-3,4-dihydroisoquinolin-1-yl)(4-methoxyphenyl)-methanone 

Relevant academic research and scientific papers

Synthesis of N-Heterocycles by Reductive Cyclization of Nitroalkenes Using Molybdenum Hexacarbonyl as Carbon Monoxide Surrogate

The development of a method that uses molybdenum hexacarbonyl [Mo(CO)6] as carbon monoxide (CO) surrogate for the palladium-catalyzed reductive cyclization of nitroalkenes into indoles or thienopyrroles is reported. Several types of nitroalkenes could be transformed into the desired products in excellent yields and in most cases with complete regioselectivities and higher yields than those previously reported with palladium/CO system.

Berbamine Analogs Exhibit Differential Protective Effects From Aminoglycoside-Induced Hair Cell Death

Hearing loss is the third most common chronic health condition in the United States and largely results from damage to sensory hair cells. Major causes of hair cell damage include aging, noise exposure, and medications such as aminoglycoside antibiotics.

Tetrahydroisoquinoline derivative and application thereof

Provided are a tetrahydroisoquinoline derivative and an application thereof. The invention relates to a compound represented by the formula (V) and a preparation method and an application thereof in medicines. In particular, the invention relates to the d

Enantioselective Oxidative Aerobic Dealkylation of N-Ethyl Benzylisoquinolines by Employing the Berberine Bridge Enzyme

N-Dealkylation methods are well described for organic chemistry and the reaction is known in nature and drug metabolism; however, to our knowledge, enantioselective N-dealkylation has not been yet reported. In this study, exclusively the (S)-enantiomers o

Synthesis and structure activity relationship of tetrahydroisoquinoline- based potentiators of GluN2C and GluN2D containing N-Methyl-D-aspartate receptors

We describe here the synthesis and evaluation of a series of tetrahydroisoquinolines that show subunit-selective potentiation of NMDA receptors containing the GluN2C or GluN2D subunits. Bischler-Napieralski conditions were employed in the key step for the

Novel hybrids from lamellarin D and combretastatin A 4 as cytotoxic agents

A new series of hybrids of lamellarin D and combretastatin A 4, 1,2-diphenyl-5,6-dihydropyrrolo [2,1-a] isoquinolines, were designed as cytotoxic agents based on principles of combination in medicinal chemistry and taking the parent compounds' different anti-proliferative mechanisms into consideration. Twenty-two novel hybrids were synthesized through a convenient route, with a key step of core pyrrole formation and evaluated for their anti-proliferative activities in vitro against K-562, A-549, SMMC-7721, SGC-7901 and HCT-116 cancer cell lines. The results showed that some hybrids had good anti-proliferative activities in low IC50 ranges.

Enantioselective synthesis of (R)-(+)- and (S)-(-)-higenamine and their analogues with effects on platelet aggregation and experimental animal model of disseminated intravascular coagulation

Optically active tetrahydroisoquinoline alkaloids, (R)-(+)-higenamine (1R) and (S)-(-)-higenamine (1 S), and their optically active 1-naphthylmethyl analogues (2 and 3), were synthesized by enantioselective hydrogenation of the corresponding dihydroisoqui

Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation

A method for preventing and/or alleviating a psychiatric disorder, and/or effectuating sedation, comprising administering a benzylisoquinoline derivative represented by General Formula (I): wherein R1, R2, R3 and X each re

TETRAHYDROISOQUINOLYL ACETAMIDE DERIVATIVES FOR USE AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to novel acetamide derivatives of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compound

Antiplatelet activity of synthetic pyrrolo-benzylisoquinolines

Pyrrolo-benzylisoquinolines were prepared as target compounds and their antiplatelet aggregation activity, adreno-receptor affinity, and cytotoxicity were screened. Compounds 1d-9d showed specific antiplatelet aggregation activity induced by arachidonic acid and collagen. Among them, 8d and 9d exhibited better activity than the reference drug, aspirin and 9d also showed inhibition of platelet aggregation by all four inducers.